Compare NUAI & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NUAI | CRBU |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.3M | 203.9M |
| IPO Year | N/A | 2021 |
| Metric | NUAI | CRBU |
|---|---|---|
| Price | $2.79 | $1.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | ★ 6.0M | 963.5K |
| Earning Date | 02-14-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $843,029.00 | ★ $9,295,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.62 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 50.89 | N/A |
| 52 Week Low | $0.32 | $0.66 |
| 52 Week High | $7.87 | $3.54 |
| Indicator | NUAI | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 37.27 | 38.12 |
| Support Level | $2.88 | $1.63 |
| Resistance Level | $4.97 | $1.73 |
| Average True Range (ATR) | 0.58 | 0.09 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 5.20 | 8.62 |
New Era Energy & Digital Inc is engaged into a fully integrated energy supplier delivering next-gen digital infrastructure and power assets. The company provides turnkey solutions to speed up data center deployment and reduce costs. The company focuses on future-proofing infrastructure for hyperscale, enterprise, and edge operators. The company provide integrated energy and digital solutions to support accelerating AI infrastructure deployment and optimize data center investments.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.